Technical Analysis for RTRX - Retrophin, Inc.

Grade Last Price % Change Price Change
grade D 18.64 1.30% 0.24
RTRX closed up 1.3 percent on Thursday, August 13, 2020, on 33 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical RTRX trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
NR7 Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Buy Signal Bullish 1.30%
Doji - Bullish? Reversal 1.30%
Lower Bollinger Band Walk Weakness 1.30%
Lower Bollinger Band Touch Weakness 1.30%
Oversold Stochastic Weakness 1.30%
Fell Below 50 DMA Bearish 2.03%
MACD Bearish Centerline Cross Bearish 2.03%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Retrophin, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orphan drugs for the treatment of rare and life-threatening diseases. The company develops treatments for Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and other catastrophic diseases. Its products include RE-021, a small molecule angiotensin receptor blocker and selective endothelin receptor antagonist for the treatment of FSGS; and RE-024, a drug that restores the disruption in the biochemical Coenzyme A pathway caused by the non-functioning PANK2 encoded enzyme. The company also develops RE-001, a recombinant fusion protein that substitutes the dystrophin that is lacking in DMD patients; and RE-003, an investigational agent for spinal muscular atrophy. The company was founded in 2011 and is based in New York, New York.
Medicine Biopharmaceutical Medical Genetics Kidney Diseases Muscular Dystrophy Spinal Muscular Atrophy Duchenne Muscular Dystrophy Genetic Genealogy Dystrophy Channelopathies

Is RTRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 21.92
52 Week Low 8.98
Average Volume 531,212
200-Day Moving Average 15.75
50-Day Moving Average 18.79
20-Day Moving Average 19.92
10-Day Moving Average 19.15
Average True Range 0.82
ADX 17.37
+DI 17.53
-DI 24.72
Chandelier Exit (Long, 3 ATRs ) 19.45
Chandelier Exit (Short, 3 ATRs ) 20.47
Upper Bollinger Band 21.80
Lower Bollinger Band 18.04
Percent B (%b) 0.16
BandWidth 18.90
MACD Line -0.20
MACD Signal Line 0.09
MACD Histogram -0.2944
Fundamentals Value
Market Cap 715.5 Million
Num Shares 38.4 Million
EPS -1.84
Price-to-Earnings (P/E) Ratio -10.13
Price-to-Sales 6.36
Price-to-Book 3.08
PEG Ratio -1.05
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.30
Resistance 3 (R3) 19.31 19.10 19.19
Resistance 2 (R2) 19.10 18.93 19.10 19.15
Resistance 1 (R1) 18.87 18.83 18.99 18.86 19.12
Pivot Point 18.66 18.66 18.72 18.66 18.66
Support 1 (S1) 18.43 18.49 18.55 18.42 18.16
Support 2 (S2) 18.22 18.39 18.22 18.13
Support 3 (S3) 17.99 18.22 18.09
Support 4 (S4) 17.98